Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
COVID-19 vaccine testing in pregnant females is necessary
Sabra L. Klein, … , Patrick S. Creisher, Irina Burd
Sabra L. Klein, … , Patrick S. Creisher, Irina Burd
Published January 14, 2021
Citation Information: J Clin Invest. 2021;131(5):e147553. https://doi.org/10.1172/JCI147553.
View: Text | PDF
Viewpoint

COVID-19 vaccine testing in pregnant females is necessary

  • Text
  • PDF
Abstract

Authors

Sabra L. Klein, Patrick S. Creisher, Irina Burd

×

Figure 1

Recommended SARS-CoV2 vaccine development pipeline.

Options: View larger image (or click on image) Download as PowerPoint
Recommended SARS-CoV2 vaccine development pipeline.
The vaccine developm...
The vaccine development pipeline has been accelerated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including overlapping of clinical trial phases and at-risk production of vaccines still in clinical trials. Despite this, it is vital that factors such as age, sex, and pregnancy be considered throughout the development process. Vaccine platforms are designed in early exploratory studies, and for SARS-CoV-2, much of this discovery was taken from platforms designed for SARS coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). These platforms are then tested in preclinical animal models for characterization including safety, toxicity, and immunogenicity. Diverse animal models including rodents and nonhuman primates of both sexes, as well as aged and pregnant animals, can help to elucidate how diverse populations will react to vaccine candidates. After preclinical studies, an investigational new drug (IND) application is submitted, and once approved, the vaccine candidate can be tested in humans in clinical trials. During the enrollment process, there should be sex-balanced enrollment as well as enrollment of older adults and pregnant women if the animal data support safety and efficacy in these groups. With the data from these trials, a biologics license application (BLA) is submitted to regulatory agencies for approval and/or EUA. When SARS-CoV-2 vaccines are widely distributed, it is vital that pregnant women have access to the vaccine and that there are empirical data supporting its safety and efficacy in pregnant women.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts